A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERUS SUNITINIB MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (CHECKMATE 214, CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVLUATION 214)
- Registry ID
- CA209-214
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Start date
- 2015-04-09
- Completion date
- 2025-09-10
- Last update
- 2014-11-20
Conditions
- RENAL CELL CARCINOMA METASTATIC
Related clinical trials
- A PHASE 2, SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB PLUS LENVATINIB IN PARTICIPANTS WITH FIRST LINE ADVANCED/METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) (KEYNOTE-B61)
- A PHASE III RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH AXITINIB VERSUS SUNITINIB MONOTHERAPY AS A FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-426)
- A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- A MULTI-CENTER, OPEN LABEL, RANDOMIZED PHASE 2 STUDY OF AGS-16C3F VS AXITINIB IN METASTATIC RENAL CELL CARCINOMA
- A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA
View on source registry